Reina Haque to Tamoxifen
This is a "connection" page, showing publications Reina Haque has written about Tamoxifen.
Connection Strength
2.719
-
Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
Score: 0.559
-
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
Score: 0.533
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.522
-
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55.
Score: 0.496
-
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318-27.
Score: 0.418
-
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
Score: 0.130
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.021
-
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
Score: 0.021
-
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008 Feb; 107(3):397-403.
Score: 0.018